The brief

Analyst view

• Chugai licensed Gero's AI-found aging targets in July 2025: upfront fee, up to about $250M in milestones, plus royalties.
• Raised $17M in June 2026, taking total equity raised to $34M.
• Still preclinical: no Gero-discovered target has yet been tested in people.

Technical approach

As reported

Data

Learning from human records, not mice

Gero trains models on long-term human health data, so targets come from how people actually age rather than from animal models that often fail to translate.

Physics

Aging as loss of resilience

A physics-style model separates slow, irreversible aging from reversible disease states, pointing to genes that push several age diseases at once.

Partnering

License targets to big pharma

Gero finds targets; partners such as Chugai and Pfizer turn them into drugs and run trials, paying Gero fees, milestones and royalties.